Phaseline

Targets › APEX1

APEX1 (DNA repair nuclease/redox regulator APEX1): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Jun 2027.

Multifunctional protein that plays a central role in the cellular response to oxidative stress. The two major activities of APEX1 are DNA repair and redox regulation of transcriptional factors. (UniProt, P27695)

Open in Phaseline: the race on APEX1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Methoxyamine
Base excision repair (BER) pathway inhibitor; enhances chemotherapy sensitivity by blockin
APEX1Phase 2Lung Adenocarcinoma; Advanced Malignant Solid NeoplasmJun 2027

Conditions

Lung Adenocarcinoma (1) Advanced Malignant Solid Neoplasm (1)

Modalities

mixed (1)

Companies

National Cancer Institute (NCI) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.